Novel Peptides in Fermented Milk with Specific <i>Lactobacillus</i> Strains Potential Antiobesity Effect: <i>In Vitro</i> and <i>in Silico</i> Analysis
Carmen Guadalupe Manzanarez-Quin, Joel Said García‐Romo, Lilia M. Beltrán‐Barrientos, María J. Torres‐Llanez, Miguel A. Mazorra‐Manzano, Adrián Hernández‐Mendoza, Aarón F. González‐Córdova, Belinda Vallejo‐Córdoba
Abstract
The objective was to investigate the potential antiobesity effect of fermented milks (FMs) with 11 strains of specific Lactobacillus strains isolated from artisanal Mexican cheeses. First, pancreatic lipase inhibitory activity (PLIA) was determined in all FMs. Then, the FM with the most PLIA was selected for peptide identification by high-performance liquid chromatography (HPLC)/tandem mass spectrometry (MS–MS) and for adipogenesis studies. FMs with Limosilactobacillus fermentum J20 (J20) displayed the highest ( p < 0.05) PLIA (81.70 ± 2.24%) and the lowest IC 50 (0.05 0.05 mg/mL) of all. Also, FM J20 inhibited lipid accumulation in a 3T3-L1 cell line. Eight novel identified peptides released by in silico digestion from the fraction with the most PLIA ( p < 0.05) presented sequences that strongly bind enzyme active sites and may be responsible for lipid accumulation inhibition during adipogenesis. Thus, FM J20 may be used for the development of a dairy product with potential antiobesity effects.